Search results
New JAK 1 Inhibitor Proves Promising in Phase 3 RA Trial
Medscape· 5 days agoThe highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients...
Doctors Test Obesity Drugs’ Limits
The New York Times via Yahoo News· 5 days agoLesa Walton suffered for years with rheumatoid arthritis. “It was awful,” said Walton, 57, who lives in Wenatchee, Washington. “I kept getting sicker and...
Shoring up blood vessels may offer new approach for treating autoimmune rheumatic diseases
Medical Xpress· 6 days agoA study from physician-scientists at the Hospital for Special Surgery (HSS) points to a potential...
Polyarthritis vs. oligoarthritis: Symptoms, causes, and more
Medical News Today· 2 days ago“Polyarthritis” and “oligoarthritis” describe the number of joints involved in arthritic conditions,...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 4 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In ...
Sjogren's Syndrome
Health· 4 days agoPeople with Sjogren’s syndrome are also at increased risk of yeast infections (candidiasis), both orally and vaginally, which may require antifungal ...
Phase 3 Trial Supports Ixekizumab in Juvenile PsA, ERA
Medscape· 4 days agoIxekizumab (Taltz), an interleukin-17A inhibitor that's already approved for the treatment of...
Joint pain at night: Causes and treatment
Medical News Today· 5 days agoJoint pain at night has several causes, including a person’s sleeping position, bedding used, and existing medical conditions, such as arthritis....
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 1 day agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
Sunset coming for rare pediatric disease treatment vouchers
The Center Square· 2 days agoPennsylvania Democratic Sen. Bob Casey, however, wants to revive the program for another decade –...
